% | $
Quotes you view appear here for quick access.

Medivation, Inc. Message Board

  • berkelygenie berkelygenie Mar 1, 2013 2:39 PM Flag

    Xtandi could be a $1B drug, but mkt cap is $8B

    MDVN and Astellas each own half less a royalty. That means MDVN is 8X overvalued or worth really $5.81 a share, which is a little more than competitor DNDN, but DNDN has much higher sales and it owns the whole patent.

80.24+0.01(+0.01%)Aug 25 4:00 PMEDT